GW_InnerBannerImages_WHS (1)

Advancing Accurate Risk Assessment & Clinical Management of Preeclampsia

Introducing the Lumella® GlyFN rapid point-of care test

Early Symptoms of Preeclampsia are often too Ambiguous for Accurate Clinical Stratification

  •  - Clinical presentations often involve uncertain indications of hypertension and proteinuria
  •  - Less than 40% of women exhibit both hypertension and proteinuria before the development of overt preeclampsia
  •  - Preeclampsia progression is unpredictable and often complicated by adverse outcomes

“ Biochemical markers can improve accurate clinical stratification and expectant management ”

Glycosylated Fibronectin (GlyFN) Levels are Elevated in Preeclampsia*

In an observational cohort of 107 pregnant women, 45 normotensive and 62 diagnosed with preeclampsia, glycosylated fibronectin (GlyFN) levels were elevated as early as the first trimester (p<0.001).

*Rasanen et al. Maternal serum glycosylated fibronectin as a point-of care biomarker for assessment of preeclampsia. American Journal of Obstetrics and Gynecology 2015;212:82.e1-9

The Lumella GlyFN Point-of Care Test Accurately Estimates Risk in Women with Suspected Preeclampsia

In a prospective, observational study (SUPERIOR study, 2016-2018), conducted in India among a cohort of 599 women suspected of preeclampsia, GlyFN as a single biochemical marker showed the highest test performance for risk stratification of preeclampsia.

Normal GlyFN
50-250 µg/mL

Correlated with normal pregnancy with high sensitivity of 98.2% and high Negative Predictive Value of 99.4%

Positive GlyFN
351-600 µg/mL

Correlated with biochemical diagnosis of preeclampsia with 98% Positive Predictive Value

High Positive GlyFN
> 600 µg/mL

Correlated with risk of severe preclampsia with 99% Positive Predictive Value

The GlyFN Test is Intended as an Aid in the Diagnosis ® Lumella of Preeclampsia in Women with Suspected Preeclampsia.

Testing period: Gestational age 13-37 weeks
  •  - New-onset hypertension •
  •  - New-onset proteinuria •
  •  - Severe headache •
  •  - Changes in vision •
  •  - Abdominal pain •
  •  - Fetal growth restriction •

Introducing the Lumella GlyFN Point-of Care Test

  •  - Measures glycosylated fibronectin (GlyFN)
  •  - Uses 5 µL finger prick blood sample
  •  -  Results in 10 minutes

Clinical Interpretation of Test Results

GlyFN range Test Result Interpretation
50-250 µg/mL Normal 99.4% Negative Predictive Value for normal pregnancy
251-350 µg/mL Abnormal Mild or Developing Preeclampsia, repeat testing in 2 weeks
351-600 µg/mL Positive 98% Positive Predictive Value for diagnosis of preeclampsia
>600 µg/mL High Positive High risk of severe preeclampsia and adverse outcomes

The importance of early detection cannot be undermined.


The importance of early detection cannot be undermined.


The importance of early detection cannot be undermined.


The importance of early detection cannot be undermined.

Request a free consultancy

It is a long established fact that a reader will be distracted by the readable content